Keratitis caused by Pseudomonas aeruginosa: treatment in the experiment

Authors

DOI:

https://doi.org/10.15587/2519-4798.2020.209167

Keywords:

еxperimental keratitis, Pseudomonas aeruginosa, treatment, levofloxacin, ciprofloxacin, tobramycin, decamethoxine

Abstract

The aim of the study was to investigate the effectiveness of treatment of keratitis caused by Pseudomonas aeruginosa using official ophthalmic forms of antibiotics, which are effective against the pathogen.

Materials and methods. Adult 36 rabbits weighing 3–3.5 kg were undergone the causing of purulent keratitis by applying a clinical strain of P. aeruginosa as a suspension of one-day culture of the microorganism at a concentration of 5×108 CFU/ml on the partially de-epithelialized (approximately 1 cm2) cornea followed by coating for 24 hours with soft contact lens made of belafilcon A (water content: 36 %, oxygen permeability DK/t:110.0). In half of the cases, microbial biofilms were pre-grown on the contact lens surfaces via incubation into the broth culture of P. aeruginosa strain.

The treatment of keratitis was performed with ocular official forms of antibiotics: levofloxacin 0.5 % (5 mg/ml), ciprofloxacin 0.3 % (3 mg/ml), tobramycin 0.3 % (3 mg/ml). Their effectiveness against the strain of P. aeruginosa was previously proven in vitro. The animals were divided into three corresponding as for severity of keratitis groups, in each of which treatment was performed with one of the three above antibiotics. In half of the cases within each group, the antibiotic was combined with the ocular official form of decamethoxine 0.02 % (0.2 mg/ml). The antibiotics were used in the mode of the most frequent instillation for the first 2 days after the onset of purulent keratitis, then 5 and 4 times a day.

The assessment included evaluation of clinical signs, culturing, ophthalmological examination of the cornea with fluorescein test and photofixation. Animals were removed from the study on days 7th, 10th, 14th (depending on the term of epithelialization of the affected cornea).

Results. Totally, 36 cases of purulent keratitis caused by P. aeruginosa in rabbits were modelled: 8 moderate (22.2 %), 13 semi-severe (36.6 %), 15 – severe (41.7 %).

Regardless of the chosen antibiotic, 10-12 hours after removal of the infected contact lens and the start of treatment, there was mostly a burst enhancement of the inflammatory process. Subsequently, the inflammatory signs showed a gradual attenuation with complete corneal epithelialization for 7th–8th days (for moderate keratitis), 10th–12th days (for severe and semi-severe in Group I and Group III) and (12th–14th days for severe and semi-severe in Group II). In comparison with the Group I (levofloxacin 0.5 %), the reducing of the corneal inflammation and lesion epithelialization within the Group II (ciprofloxacin 0.3 %), was 1–2 days delayed. The use of 0.3 % tobramycin (Group III) provided the highest control of purulent inflammation during the first three to four days, but further there was a slowdown in the positive dynamics and delayed epithelialization compared with Group I. For all study groups, the use of combination antibiotic therapy with decamethoxine was accompanied by acceleration in regression of purulent-inflammatory lesions, especially due to a decrease in conjunctival response and pyorrhea.

Among the outcomes, in most of cases (69.5 %) there were areas of corneal opaque turbidity of various sizes. Total leucoma was noted in more than a third of cases; always due to severe keratitis. It was managed to avoid the complications that could lead to eye loss (corneal abscess, perforation, malacia) in all animals.

The culturing from the surface of the eye has shown a decrease from 100 % to 63.9 % in presence P. aeruginosa after 48 hours and the whole pathogen disappearance after 3 days of treatment. However, in 11 of 15 severe keratitis (30.6 % of total observations) microbiological tests of the cornea, obtained after removal of animals, were positive as for P. aeruginosa even after complete lesion epithelialization.

Conclusions. Treatment of experimental keratitis caused by P. aeruginosa, with antibiotics, to which the sensitivity of pathogen is proven, in the mode of the earliest and most frequent instillations on the first 48 hours in combination with removal of purulent masses provides reducing of inflammation, restoring of cornea surface and prevents the most serious complications, e.g. corneal perforations and keratomalacia.

Early and active antimicrobial treatment with effective drugs led to the elimination of P. aerugenosa from the ocular surface in the first 2–3 days. However, in 30.6 % of cases there was no complete eradication of the pathogen from the cornea.

The choice of antibiotic from those, to which the sensitivity of P. aerugenosa is proven, did not have a significant influence on treatment outcome. Concomitant use of decamethoxine makes better effect and somewhat improves the results

Author Biographies

Nataliia Malachkova, National Pirogov Memorial Medical University Pirogova str., 56. Vinnitsya, Ukraine, 21018

PhD, Associate Professor, Head of Department

Department of Ophtalmology

Nelia Kryvetska, National Pirogov Memorial Medical University Pirogova str., 56. Vinnitsya, Ukraine, 21018

Postgraduate Student

Department of Ophtalmology

Volodymyr Kryvetskyi, National Pirogov Memorial Medical University Pirogova str., 56. Vinnitsya, Ukraine, 21018

PhD, Associate Professor

Department of Surgery No. 1

References

  1. Güell, J. L. (Ed.) (2015). Cornea. Vol. 6. ESASO Course Series. Basel: Karger, 127. doi: http://doi.org/10.1159/000381489
  2. Raphalyuk, S. Y. (2015). The possibility of metabolic correction of pathological disorders in induced keratitis in animals with dry eye syndrome. Ophthalmology, 2 (2), 211–120.
  3. Zamani, M., Panahi-Bazaz, M., Assadi, M. (2015). Corneal collagen cross-linking for treatment of non-healing corneal ulcers. Journal of Ophthalmic and Vision Research, 10 (1), 16–20. doi: http://doi.org/10.4103/2008-322x.156087
  4. Gokhale, N. (2008). Medical management approach to infectious keratitis. Indian Journal of Ophthalmology, 56 (3), 215–220. doi: http://doi.org/10.4103/0301-4738.40360
  5. Farias, R., Pinho, L., Santos, R. (2017). Epidemiological profile of infectious keratitis. Revista Brasileira de Oftalmologia, 76 (3), 116–120. doi: http://doi.org/10.5935/0034-7280.20170024
  6. Wang, M., Smith, W. A., Duncan, J. K., Miller, J. M. (2017). Treatment of Pseudomonas Keratitis by Continuous Infusion of Topical Antibiotics With the Morgan Lens. Cornea, 36 (5), 617–620. doi: http://doi.org/10.1097/ico.0000000000001128
  7. Tacconelli, E., Carrara, E., Savoldi, A., Kattula, D., Burkert, F. (2017). Global priority list of antibiotic-resistant bacteriatoguideresearch, discovery, and development of new antibiotics World Health Organization. Available at: https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf
  8. Green, M., Apel, A., Stapleton, F. (2008). Risk Factors and Causative Organisms in Microbial Keratitis. Cornea, 27 (1), 22–27. doi: http://doi.org/10.1097/ico.0b013e318156caf2
  9. Jin, H., Parker, W. T., Law, N. W., Clarke, C. L., Gisseman, J. D., Pflugfelder, S. C. et. al. (2017). Evolving risk factors and antibiotic sensitivity patterns for microbial keratitis at a large county hospital. British Journal of Ophthalmology, 101 (11), 1483–1487. doi: http://doi.org/10.1136/bjophthalmol-2016-310026
  10. Zimmerman, A. B., Nixon, A. D., Rueff, E. M. (2016). Contact lens associated microbial keratitis: practical considerations for the optometrist. Clinical Optometry, 8, 1–12. doi: http://doi.org/10.2147/opto.s66424
  11. Dart, J. K. G., Seal, D. V. (1988). Pathogenesis and therapy of pseudomonas aeruginosa keratitis. Eye, 2 (S1), S46–S55. doi: http://doi.org/10.1038/eye.1988.133
  12. Rykov, S. A., Lemziakov, G. G., Bakbardina, L. M., Bakbardina, I. I. (2009). Zabolievaniya rogovitsy. Kyiv, 244.
  13. Lambert, R. J. W., Hanlon, G. W., Denyer, S. P. (2004). The synergistic effect of EDTA/antimicrobial combinations on Pseudomonas aeruginosa. Journal of Applied Microbiology, 96 (2), 244–253. doi: http://doi.org/10.1046/j.1365-2672.2004.02135.x
  14. Melezhyk, I. A., Yavorskaya, N. V., Shepelevich, V. V., Kokozay, V. N. (2013). The role of biofilms in pseudomonas aeruginosa endogenous infections. Biulleten Orenburgskogo nauchnogo centra UrO RAN, 3.Available at: http://elmag.uran.ru:9673/magazine/Numbers/2013-3/Articles/5Melezhik(2013-3).pdf
  15. Mulcahy, L. R., Isabella, V. M., Lewis, K. (2013). Pseudomonas aeruginosa Biofilms in Disease. Microbial Ecology, 68 (1), 1–12. doi: http://doi.org/10.1007/s00248-013-0297-x
  16. O’Callaghan, R., Caballero, A., Tang, A., Bierdeman, M. (2019). Pseudomonas aeruginosa Keratitis: Protease IV and PASP as Corneal Virulence Mediators. Microorganisms, 7 (9), 281. doi: http://doi.org/10.3390/microorganisms7090281
  17. Marquart, M. E. (2011). Animal Models of Bacterial Keratitis. Journal of Biomedicine and Biotechnology, 2011, 1–12. doi: http://doi.org/10.1155/2011/680642
  18. McClellan, S., Jiang, X., Barrett, R., Hazlett, L. D. (2015). High-Mobility Group Box 1: A Novel Target for Treatment of Pseudomonas aeruginosa Keratitis. The Journal of Immunology, 194 (4), 1776–1787. doi: http://doi.org/10.4049/jimmunol.1401684
  19. Malachkova, N. V., Kryvetska, N. V., Vovk, I. M., Kryvetskyi, V. F. (2020). Pat. No. 141155. Method of modeling of pseudomonad keratitis in rabbits. MPK: C12Q 1/00, C12R 1/385. G09B 23/28. No. u201908915. declared: 23.07.19; published: 25.03.2020, No. 6.
  20. Malachkova, N. V., Kryvetska, N. V., Vovk, I. M., Kryvetskyi, V. F. (2020). Pat. No. 141156. Method of modeling of associated with contact lens pseudomonad keratitis in rabbits. MPK: C12Q 1/00, G09B 23/28, C12R 1/385. declared: 23.07.19; published: 25.03.2020, No. 6.
  21. Malachkova, N. V., Kryvetska, N. V., Vovk, I. M., Kovalenlo, I. M., Kryzhanovskaya, A. V. (2020). Models of experimental pseudomonas keratitis: microbiological and clinical aspects. Reports of Vinnytsia National Medical University, 24 (1), 129–133. doi: http://doi.org/10.31393/reports-vnmedical-2020-24(1)-25
  22. Vovk, I. M., Kryvetska, N. V., Burkot, V. M., Dudar, A. O., Kulik, A. V. (2020). Microbiological grounds for antimicrobial treatment of experimental pseudomonal keratitis. Reports of Vinnytsia National Medical University, 24 (1), 114–117. doi: http://doi.org/10.31393/reports-vnmedical-2020-24(1)-21
  23. Lin, A., Rhee, M. K., Akpek, E. K., Amescua, G., Farid, M., Garcia-Ferrer, F. J. et. al. (2019). Bacterial Keratitis Preferred Practice Pattern®. Ophthalmology, 126 (1), 1–55. doi: http://doi.org/10.1016/j.ophtha.2018.10.018
  24. Rasamiravaka, T., Labtani, Q., Duez, P., El Jaziri, M. (2015). The Formation of Biofilms by Pseudomonas aeruginosa: A Review of the Natural and Synthetic Compounds Interfering with Control Mechanisms. BioMed Research International, 2015, 1–17. doi: http://doi.org/10.1155/2015/759348
  25. Nazarchuk, O., Chereshniuk, I., Nazarchuk, G., Palii, D. et. al. (2019). Current antiseptics: a study on their antimicrobial activity and toxic effects on the corneal epithelium. Oftalmologicheskii Zhurnal, 80 (3), 26–31. doi: http://doi.org/10.31288/oftalmolzh201932631
  26. Bezwada, P., Clark, L. A., Schneider, S. (2007). Intrinsic cytotoxic effects of fluoroquinolones on human corneal keratocytes and endothelial cells. Current Medical Research and Opinion, 24 (2), 419–424. doi: http://doi.org/10.1185/030079908x261005

Downloads

Published

2020-07-31

How to Cite

Malachkova, N., Kryvetska, N., & Kryvetskyi, V. (2020). Keratitis caused by Pseudomonas aeruginosa: treatment in the experiment. ScienceRise: Medical Science, (4 (37), 21–28. https://doi.org/10.15587/2519-4798.2020.209167

Issue

No. 4 (37) (2020)

Section

Medical Science

License

Copyright (c) 2020 Nataliia Malachkova, Nelia Kryvetska, Volodymyr Kryvetskyi

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.

Authors, who are published in this journal, agree to the following conditions:

1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.

 2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.